Business
Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"PITTSBURGH, June 08, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast taking place June 9-11, 2020.\n Details for the presentation are as follows: Goldman Sachs 41st Annual Global Healthcare Conference Webcast Presentation Date: Wednesday, June 10, 2020 Presentation Time: 1:20 p.m. ET Webcast: https://kvgo.com/GSHC/krystal-biotech-june-2020 A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at: http://ir.krystalbio.com/events-and-presentations/events. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal, including but not limited to statements about the development of Krystal’s product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of bercolagene telserpavec (“B-VEC”) and KB105, the clinical utility of B-VEC and KB105 and Krystal’s plans for filing of regulatory approvals and efforts to bring B-VEC and KB105 to market, the market opportunity for and the potential market acceptance of B-VEC and KB105, plans to pursue research and development of other product candidates, the sufficiency of Krystal’s existing cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availabi...